Following a funding round, Nintx (Next Innovative Therapeutics) has appointed Stephani Saverio as CEO, with Miller Freitas assuming the role of CDO (Chief Development Officer) and Cristiano Guimarães continuing as CSO (Chief Scientific Officer). The company plans to establish an innovative approach to tackling multifactorial diseases in Brazil’s pharmaceutical industry.
Who to call at Nintx, and when
A new leader at Nintx brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Nintx raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Nintx, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nintx. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Nintx
Location
Sao Paulo, Sao Paulo, Brazil
About
Nintx develops a new generation of medicines leveraging biodiversity, primarily from Brazil. One of its key innovations is a broader approach to tackling multifactorial diseases, caused by genetic and environmental factors as well as their interactions via the human gut microbiome. Multifactorial diseases include metabolic, immunological, cancer, and brain disorders. Nintx develops therapies targeting biological pathways directly and indirectly through gut microbiome modulation—both closely linked to the onset or worsening of multifactorial diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nintx changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Sao PauloBiotechnologyHealth CarePharmaceutical